AstraZeneca is developing a next-generation long-acting antibody for pre-exposure prophylaxis of COVID-19, which it plans to make available in the second half of 2023.
Formulary Watch
Latest News
All News
Advertisement
Evio is launching a new pharmacy solution that leverages Flipt’s proprietary, cloud-based benefit administration and patient engagement platforms.
Three out of four health plans scored a “C” or an “F” because of utilization management restrictions they place on medication for autoimmune conditions.
In this video, Dea Belazi, president and chief executive officer of AscellaHealth, discusses how payers will approach specialty drugs.
The Inflation Reduction Act’s cap on annual out-of-pocket spending and changes to coverage gaps could save Medicare patients more than $1,000 on heart failure medications.
The Association for Accessible Medicines’ report indicates plans, especially those in Medicare, are slower to prefer first generics.
Amazon Prime members can access generic medications from an eligible list with free delivery for an additional $5 a month.
The Peripheral and Central Nervous System Drugs Advisory Committee meeting is scheduled for March 22, 2023, to review Biogen’s tofersen.
Price Edge compares direct-to-consumer pricing with insurance pricing for generic drugs. It is an optional product being offered to plans.
Once-daily, oral SGLT2 inhibitor Brenzavvy has been shown to reduce blood sugar and improve glycemic control.
Advertisement
Dea Belazi of AscellaHealth talks about the challenges payers will face as they confront the high costs associated with specialty drugs.
A phase 3 trial showed that Jardiance reduced the risk of kidney disease progression or cardiovascular death in adults with chronic kidney disease by 28% compared with placebo. An FDA decision is expected in the second half of 2023.
Moderna plans to submit to the FDA its investigational mRNA vaccine, RNA-1345, for respiratory syncytial virus (RSV) in the first half of 2023.
Lilly expects topline results from the confirmatory phase 3 trial in the second quarter of 2023 and plans to submit for full approval.
This is the fourth indication for the Bruton’s tyrosine kinase inhibitor.
Tukysa with trastuzumab is indicated for second-line treatment of HER2-positive metastatic colorectal cancer, the first such therapy for this cancer.
There are currently no medications approved for the treatment of NASH, which can lead to cirrhosis, eventual liver failure, cancer and death. The FDA has assigned a PDUFA target action of June 22, 2023, for the therapy, obeticholic acid.
Annual savings from biosimilars could be more $100 billion by 2026, according to IQVIA’s latest Global Use of Medicines report.
Patient advocates discussed the difficulties that formulary policies and lack of transparency place on those with chronic disease at an ICER sponsored webinar.
The Inflation Reduction Act’s cap on out-of-pocket costs for insulin is likely to improve outcomes for almost half of Medicare’s insulin users.
While ICER found that overall major payer coverage policies are in line with the organization’s fair access criteria, many payers do not provide adequate transparency into clinical coverage criteria.
A new membership program, SmartRx, offers consumers savings on prescriptions, as well as office visits, eye care, vaccines and pet meds.
Lawsuit accuses the companies of using unlawful, unfair, and deceptive practices.
Rykindo is a bi-weekly long-acting risperidone injection to treat patients with schizophrenia and bipolar 1 in adults.
Optum Rx’s Humira biosimilar strategy for 2023 was set up to allow for the most value in the first year, said CEO Heather Cianfrocco.
This update removes a previous limitation that it could not be used as the first therapy.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Tackling Health Inequities Through Collaboration and Community-Based Care
2
Optimal Physical Activity for Preventing Digestive System Cancers
3
Fulton County Leaders Discuss Closing Health Gaps and Strengthening Behavioral Health Systems
4
Celiac Disease and Thyroid Disease in Adolescence Linked to the Development of Type 1 Diabetes in Adulthood
5
